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In many programs providing antiretroviral therapy (ART), clinicians report substantial patient attrition; however,
there are no consensus criteria for deﬁning patient loss to follow-up (LTFU). Data on a multisite human immuno-
deﬁciency virus (HIV) treatment cohort in Lusaka, Zambia, were used to determine an empirical ‘‘days-late’’
deﬁnition of LTFU among patients on ART. Cohort members were classiﬁed as either ‘‘in care’’ or LTFU as of
December 31, 2007, according to a range of days-late intervals. The authors then looked forward in the database to
determine which patients actually returned to care at any point over the following year. The interval that best
minimized LTFU misclassiﬁcation was described as‘‘best-performing.’’ Overall, 33,704 HIV-infected adults onART
were included. Nearly one-third (n ¼ 10,196) were at least 1 day late for an appointment. The best-performing
LTFU deﬁnition was 56 days after a missed visit, which had a sensitivity of 84.1% (95% conﬁdence interval (CI):
83.2, 85.0), speciﬁcity of 97.5% (95% CI: 97.3, 97.7), and misclassiﬁcation of 5.1% (95% CI: 4.8, 5.3). The 60-day
threshold performed similarly well, with only a marginal difference (<0.1%) in misclassiﬁcation. This analysis
suggests that  60 days since the last appointment is a reasonable deﬁnition of LTFU. Standardization to empir-
ically derived deﬁnitions of LTFU will permit more reliable comparisons within and across programs.
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Abbreviations: ART, antiretroviral therapy; CI, conﬁdence interval; HIV, human immunodeﬁciency virus.
In sub-Saharan Africa, services for human immunodeﬁ-
ciency virus (HIV) care and treatment have expanded rap-
idly over the past decade and have provided life-saving
antiretroviral therapy (ART) to over 2 million infected
adults and children (1). Despite demonstrable health gains
among enrollees, however, clinicians in many programs in
the region are now reporting substantial patient attrition. In
a study of 13 African cohorts, for example, Braitstein et al.
(2) noted an average of 15% loss to follow-up at 12 months
following ART initiation, with variability ranging from 0%
to 44% across programs. In a review of 33 African cohorts,
Rosen et al. (3) calculated a weighted mean attrition rate
of 1.8%–3.3% per month, which they attributed largely to
follow-up losses.
Although loss to follow-up is a commonly reported met-
ric, it has no consensus deﬁnition. ‘‘Lateness’’ for scheduled
appointments is often used to describe the phenomenon, but
the actual time intervals employed vary greatly among pro-
grams. Our research group in Zambia, for example, has
classiﬁed patients who are more than 30 days past their last
scheduled appointment date as ‘‘late’’ in published reports
(4–11). Me ´decins Sans Frontie `res (Doctors Without Bor-
ders) has deﬁned loss to follow-up as being more than 2
months late for a scheduled appointment (12, 13); Yu et al.
(14) used a 3-month interval from the time of a missed
appointment in northern Malawi. Time since the last clinic
visit has also been used to deﬁne loss to follow-up. Patients
included in the ART-LINC collaboration were classiﬁed as
lost to follow-up when 6 months had elapsed since their last
visit (2, 15). A 3-month threshold from the last visit was
used by Wools-Kaloustian et al. (16) to deﬁnefollow-up loss
in western Kenya. Before we can better understand the
924 Am J Epidemiol 2010;171:924–931phenomenon of patient attrition, there is a need for standard-
ized deﬁnitions of loss to follow-up based on empirical
evidence, to permit consistent comparisons across and
within programs.
MATERIALS AND METHODS
We analyzed data from a large programmatic cohort in
Lusaka, Zambia, to determine the best-performing criterion
for classifying patients who are late for scheduled appoint-
ments. The multisite Lusaka ART program is administered
by the Zambian Ministry of Health and its local partners,
with substantial support being provided by the President’s
Emergency Plan for AIDS Relief; the Global Fund for
AIDS, Tuberculosis, and Malaria; and other donors. Clinical
and programmatic characteristics have been described in
detail elsewhere (4, 5). Brieﬂy, HIV-infected adults and
children are screened for ART eligibility on the basis of
CD4þ cell count and clinical staging across 18 public sector
sites. ART is initiated on the basis of national criteria (17),
which closely follow those of the World Health Organiza-
tion (18, 19). Adults initiating ART undergo an intensive
clinical visit schedule over the ﬁrst 3 months for assessment
of potential side effects and encouragement of adherence;
patients without complications proceed to once-monthly
pharmacy visits and quarterly clinical visits. Medical history
and appointment information is captured in an electronic
medical record (20). From this database, data staff generate
weekly lists of patients with missed appointments. Commu-
nity health workers use collected locator information to
contact patients with missed visits at their homes to encour-
age and facilitate clinic attendance (21).
We developed an empirical approach to determine the
‘‘most efﬁcient’’ deﬁnition of loss to follow-up (Figure 1)
based on sensitivity and speciﬁcity to predict a return to care
in the subsequent year. The source population for our anal-
ysis was all ART-naive HIV-infected adults initiating HIV
treatment at 18 Lusaka sites between April 1, 2004, and
December 31, 2007. Patients who were active and those
whowerelateforaclinicalorpharmacyvisitasofDecember
31, 2007, were included in the analysis. Patients who had
formally withdrawn from the program or who had died prior
to that date were excluded (22). We categorized loss to
follow-up on the basis of number of days late, using thresh-
olds from  1 day to  182 days (i.e., 26 weeks). For each
cutpoint, we looked forward in our data set—from January
1, 2008, to December 31, 2008—to determine the propor-
tion of persons who returned to care within the subsequent 1
year.
We evaluated the performance of the various deﬁnitions
by calculating their sensitivity and speciﬁcity for determin-
ing loss to follow-up status and ﬁtting receiver operating
Figure 1. Method used to evaluate the performance of many different intervals for deﬁning loss to follow-up (LTFU) in a multisite human
immunodeﬁciency virus treatment cohort, Lusaka, Zambia, 2004–2007. Once a speciﬁc interval is selected, patients are classiﬁed as ‘‘active’’
or LTFU as of December 31, 2007. We then document whether they return to care during the 2008 calendar year. Each bar represents a patient
who has started antiretroviral therapy. The black portion represents the period for which a patient is active in care and not late for an appointment. If
a patientbecomeslate for an appointmentduring the courseof his or her follow-up, this is depictedby a thin blackline. Thewhite portion of each bar
represents the interval in which lateness for a scheduled visit is ‘‘allowable’’ and not considered LTFU. The length of this white bar represents the
threshold deﬁnition that we are primarily examining in this analysis. In the 2 panels, we demonstrate how differences in the LTFU threshold can
affecttheclassiﬁcationof patients.Patientscategorized asa are LTFUasof December31,2007,anddonot returntocare duringthenextyear (true
positives). Those categorized as b were originally classiﬁed as LTFU but return to care (false positives). Those in c are classiﬁed as active on
December 31, 2007, but fail to return for subsequent appointments (false negatives). Group d comprises patients who are classiﬁed as active at the
cutoff date and remain active during the coming year (true negatives). Using this 2 3 2 table, we are able to calculate sensitivity (a/a þ c) and
speciﬁcity (d/b þ d) for each LTFU threshold.
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as persons who were classiﬁed as follow-up losses on
December 31, 2007, but returned to care in the subsequent
year. The false-positive rate for each cutoff deﬁnition of loss
to follow-up (LTFU) was calculated as (non-LTFU preva-
lence) 3 (1   speciﬁcity). ‘‘False-negative’’ cases for each
cutoff deﬁnition of loss to follow-up were persons who were
classiﬁed as active but never returned for later visits; this
was deﬁned as (LTFU prevalence) 3 (1   sensitivity). The
cutpoint that minimized the sum of false positives and false
negativeswas considered the most efﬁcient loss to follow-up
threshold—that is, a weighted sum of the sensitivity and
speciﬁcity based on the prevalence of cases (23). If 2 or
more time intervals had the same misclassiﬁcation rate,
we designated the shorter interval as the more efﬁcient
deﬁnition of loss to follow-up.
To determine whether length of enrollment affected the
performance of our calculated deﬁnitions of loss to follow-
up, we performed secondary analyses using different ‘‘en-
rollment cohorts.’’ We stratiﬁed patients according to the
calendar year in which they started ARTand, using the same
method, calculated the optimal days-late threshold for
deﬁning loss to follow-up. These cohorts comprised persons
starting ART between: 1) April 1, 2004, and December 31,
2004; 2) January 1, 2005, and December 31, 2005;
3)January 1, 2006, and December 31, 2006;and 4) January 1,
2007, and December 31, 2007. For each of these cohorts,
December 31, 2007, was used as the cutpoint to classify
patients as lost to follow-up, and we looked ahead 1 year to
determine their subsequent status.
Two additional secondary analyses were performed. First,
we restricted our study population to persons who were at
least 1 day late for their clinical or pharmacy appointment as
of December 31, 2007. We excluded the subset of patients
who were active in care and had their next appointment
following this cutoff date, because they could only contrib-
ute to ‘‘false-negative’’ misclassiﬁcation. In contrast, those
included in this subanalysis could potentially contribute to
both ‘‘false-positive’’ and ‘‘false-negative’’ misclassiﬁca-
tion, depending on the deﬁnition of loss to follow-up used.
Secondly, we tested the performance of deﬁnitions of loss to
follow-up at other cutoff dates. For the primary analysis,
December 31, 2007, had been chosen as a matter of conve-
nience, but an underlying tenet of this method is that any
date can be used, provided that a sufﬁcient amount of
follow-up time is available afterwards. We conducted this
secondary analysis to conﬁrm the robustness of our ﬁndings
when other dates were used.
All analyses were performed using SAS, version 9.13
(SAS Institute Inc., Cary, North Carolina). Use of these pro-
grammatic data was approved by the University of Zambia
(Lusaka, Zambia) Research Ethics Committee and the
Figure 2. Time from the last missedvisit to December 31, 2007 (the date for determining loss to follow-up) in a multisite human immunodeﬁciency
virus treatment cohort, Lusaka, Zambia, 2004–2007. Histograms are stratiﬁed by year of enrollment: A) 2004; B) 2005; C) 2006; D) 2007.
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bama) Institutional Review Board.
RESULTS
Between April 1, 2004, and December 31, 2007, 40,700
HIV-infected adults initiated ART at 18 program sites in
Lusaka. As of December 31, 2007, 6,996 (17.2%) were
known to have formally withdrawn from the program or
to have died and were thus excluded. Of the remaining
33,704 patients, 23,508 (69.7%) had attended their last ap-
pointment and had a subsequent one scheduled and were
thus considered ‘‘active.’’ Nearly one-third of patients
(n ¼ 10,196 or 30.3%) were at least 1 day late for a clinical
or pharmacy visit. The median interval from the last missed
appointment to the December 31, 2007, eligibility cutpoint
was 123 days (interquartile range, 21–462). The distribu-
tions of the yearly enrollment cohorts are shown in Figure 2.
We evaluated the performance of various cutpoints for
deﬁning loss to follow-up, including sensitivity, speciﬁcity,
and misclassiﬁcation rate (Table 1), and then ﬁtted receiver
operating characteristic curves to these data (Figure 3). On
the basis of our method, the best-performing deﬁnition was
 56 days. This threshold had the lowest misclassiﬁcation
rate (5.1%; 95% conﬁdence interval (CI): 4.8, 5.3), along
with a sensitivity of 84.1% (95% CI: 83.2, 85.0), speciﬁcity
of 97.5% (95% CI: 97.3, 97.7), a positive predictivevalue of
88.7% (95% CI: 87.9, 89.5), and a negative predictive value
of 96.3% (95% CI: 96.1, 96.5). Interestingly, misclassiﬁca-
tion rates for  54 days to  69 days differed by less than
0.1% when compared with the misclassiﬁcation rate of  56
days (Figure 4, part A).
When we performed analyses of separate enrollment co-
horts, the most efﬁcient deﬁnition of loss to follow-up ap-
peared to shorten as duration of time in the program
decreased (Table 2). For persons enrolled for 3 years or
longer (i.e., those who started ART prior to December 31,
Table 1. Performance of Various Time Intervals After a Missed Appointment in Deﬁning Loss to Follow-up Among
Patients Enrolled in a Multisite Human Immunodeﬁciency Virus Treatment Cohort Between April 1, 2004, and
December 31, 2007, Lusaka, Zambia
LTFU
Threshold
a, days
No. Classiﬁed
as LTFU
No. Who Subsequently
Returned to Care Sensitivity, % Speciﬁcity, % Misclassiﬁcation, %
 7 9,269 3,308 92.6 87.9 11.2
 14 8,397 2,539 91.0 90.7 9.3
 21 7,686 1,907 89.8 93.0 7.6
 28 7,063 1,377 88.3 95.0 6.3
 35 6,730 1,110 87.3 95.9 5.7
 42 6,499 938 86.4 96.6 5.4
 49 6,295 798 85.4 97.1 5.2
 56
b 6,104 688 84.1 97.5 5.1
 63 5,958 617 83.0 97.7 5.1
 70 5,841 576 82.8 97.9 5.2
 77 5,714 528 80.6 98.1 5.3
 84 5,603 493 79.4 98.2 5.4
 91 5,514 462 78.5 98.3 5.5
 98 5,431 441 77.5 98.4 5.6
 105 5,333 421 76.3 98.5 5.8
 112 5,235 403 75.1 98.5 6.0
 119 5,147 383 74.0 98.6 6.1
 126 5,073 371 73.1 98.6 6.3
 133 4,991 356 72.0 98.7 6.4
 140 4,910 344 70.9 98.7 6.6
 147 4,837 329 70.0 98.8 6.7
 154 4,780 317 69.3 98.8 6.8
 161 4,724 309 68.6 98.9 6.9
 168 4,656 297 67.7 98.9 7.1
 175 4,581 286 66.7 99.0 7.2
 182 4,511 275 65.8 99.0 7.4
Abbreviation: LTFU, loss to follow-up.
a For illustrative purposes, we show the performance of different LTFU time periods in 7-day increments.
b The best-performing deﬁnition of LTFU coincided with the 56-day intervals.
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days. For persons enrolled for at least 2 years but less than 3
years (i.e., January 1, 2005– December 31, 2005), the most
efﬁcient deﬁnition of follow-up loss was 63 days. For per-
sons enrolled for at least 1 year but less than 2 years (i.e.,
January 1, 2006–December 31, 2006), the most efﬁcient
deﬁnition of follow-up loss was 60 days. For persons en-
rolled for less than 1 year (i.e., January 1, 2007–December
31, 2007), the most efﬁcient deﬁnition of follow-up loss was
47 days.
We restricted the study population to persons who were at
least 1 day late for their last clinical or pharmacy appoint-
ment as of December 31, 2007. When we evaluated the
performance of loss to follow-up classiﬁcations at different
time intervals, the best-performing deﬁnition was  56 days,
identical to our primary analysis (Figure 4, part B). The
proportion of patients misclassiﬁed at this threshold was
12.8% (95% CI: 12.1, 13.4); sensitivity was 89.8% (95%
CI: 89.0, 90.6), speciﬁcity was 83.5% (95% CI: 82.3, 84.6),
positive predictive value was 88.7% (95% CI: 87.9, 89.5),
and negative predictive value was 85.0% (95% CI: 83.6,
86.1). We then evaluated the performance of deﬁnitions of
loss to follow-up at cutoff dates other than December 31,
2007. This analysis yielded results nearly identical to those
of our primary analysis (Figure 4, part C). The most efﬁcient
deﬁnitions using alternative cutoff days were: June 30, 2007
(62 days); September 30, 2007 (60 days); March 31, 2008
(62 days); and June 30, 2008 (59 days).
DISCUSSION
Minimizing the misclassiﬁcation of patients lost to
follow-up has great importance in cohort analyses and pro-
grammatic reporting. When patients are prematurely classi-
ﬁed as lost to follow-up, they can be incorrectly censored
and fail to contribute person-time to an analysis, thus con-
tributing to underestimation of program coverage over time.
Figure 3. Receiveroperator characteristic curves for adults initiating
antiretroviral therapy in Lusaka, Zambia, between April 1, 2004, and
December 31, 2007, by year of enrollment.
Figure 4. Proportions of patients misclassiﬁed as active or lost to
follow-up across different time intervals among adults initiating anti-
retroviral therapy in Lusaka, Zambia, between April 1, 2004, and
December 31, 2007. In a series of sensitivity analyses, we stratiﬁed
the overall population according to year of enrollment (part A); re-
stricted our study population to only those patients who were at least
1 day late for a scheduled visit on December 31, 2007 (part B); and
repeated our analysis using several cutoff dates other than December
31, 2007 (part C).
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liberal deﬁnitions of loss to follow-up to maximize the pos-
sibility of return. When this window is too wide, however,
patients may be misclassiﬁed as active even when they will
not return. A large proportion may in fact have died (14, 21,
24, 25). Herewe have proposed a simple empirical approach
to deﬁning loss to follow-up in a way that can standardize
program evaluation reports and research comparisons, both
across and within programs. In our multisite program in
Lusaka, use of  56 days’ lateness for a scheduled visit
led to the fewest misclassiﬁcations of loss to follow-up.
However, given the minute differences in misclassiﬁcation
seen in the intervals immediately preceding and following
56 days (Figure 4), we suggest the use of 2 months—or 60
days—as the lateness threshold for deﬁning loss to follow-
up. This interval is longer than the deﬁnition of 30 days that
we have used in our previous program evaluations (4–11)
but shorter than that used in many other programs (2,
14–16).
The strengths of this method are its relative simplicity and
empiric approach, suggesting a standardized, evidence-
based deﬁnition of loss to follow-up. We recognize several
limitations to our analysis. This technique only considers
the patient’s last missed visit; we did not take into account
previous missed visits and thus failed to utilize all available
data. Our approach was designed to most accurately classify
patients as either active or lost to follow-up at a single point
in time, as would be required for program reporting or co-
hort analysis. This method is not conducive to more com-
plicated analysis regarding factors associated with loss to
follow-up, since persons who died or withdrew from the
program prior to the date of classiﬁcation were excluded.
Although our deﬁnition of follow-up loss was robust across
a number of sensitivity analyses, it is unknown whether
it can be generalized to locations outside of our urban
primary-care setting in Zambia. Several program character-
istics may have affected our results, including an active
patient tracking system for missed visits, the provision of
free ART, and the use of sophisticated electronic medical
records linking care data across multiple clinics. Similar
analyses should be performed in other settings to determine
how these and other program features inﬂuence optimal
deﬁnitions of loss to follow-up.
Our method begins with the selection of an arbitrary date
(i.e., December 31, 2007), from which patients are catego-
rized as active or lost to follow-up according to a range of
days-late thresholds. Once categorized as lost to follow-up,
all patients are provided the same opportunity to return to
care irrespective of time since the last visit; in this analysis,
this was the calendar year of January 1, 2008–December 31,
2008. We recognize, however, that the likelihood that such
a person will return to care varies inversely with the length
of time since his or her missed visit. A patient whose last
scheduled visit was 2 years ago, for example, is far less
likely to return to care than someone who missed a visit just
2 months ago. Because the chances of such misclassiﬁcation
may be reduced among ‘‘older’’ enrollment cohorts, the
performance of the ‘‘most efﬁcient’’ deﬁnition of loss to
follow-up was generally better in those groups. While spec-
iﬁcity remained approximately the same, sensitivity in-
creased among persons who had been enrolled in the
program for a longer time (Table 2).
When we examined the proportion of ART patients mis-
classiﬁed as either active or lost to follow-up, the greatest
change in misclassiﬁcation was seen over the ﬁrst 30 days.
Thereappearedtobeabroadnadirinthe 30-to90-dayrange,
followed by a slight increase over the intervals that followed.
While our method can determine the best-performing deﬁ-
nition of loss to follow-up with great precision, as Figure 4
demonstrates, there probably exists a range of ‘‘acceptable’’
thresholds from the program perspective. This ﬂexibility
prompted us to recommend a 60-day threshold for deﬁning
loss to follow-up, which we found to be more intuitive and
only marginally less efﬁcient than the best-performing
56-day threshold in our setting.
We observed differences in the optimal deﬁnition of loss
to follow-up when stratifying by enrollment date. Persons
who had enrolled most recently had the shortest loss to
follow-up windows; as time in the program increased, so
did the length of this best-performing interval. The reasons
behind this ﬁnding are unclear, but our exclusion of deaths
and program withdrawals from the analysis may have
played an important role. If 1 group were to have better
status ascertainment—a likely scenario for earlier (vs. later)
enrollment cohorts—then the differential exclusion of these
patients could contribute to the variability from stratum to
stratum.
When we investigated the interval between the missed
visit and December 31, 2007, we found a bimodal distribu-
tion of these data for each enrollment cohort. A common
Table 2. The Best-Performing Deﬁnition of Loss to Follow-up in a Multisite Human Immunodeﬁciency Virus Treatment Cohort, by Year of
Enrollment, Lusaka, Zambia, 2004–2007
a
Enrollment Dates
for Cohort
Best-Performing Deﬁnition of Loss to Follow-up
No. of Days Misclassiﬁcation, % 95% CI Sensitivity, % 95% CI Speciﬁcity, % 95% CI
April 1, 2004–December 31, 2004  70 3.0 2.5, 3.6 93.5 91.7, 95.0 98.1 97.5, 98.6
January 1, 2005–December 31, 2005  63 3.7 3.3, 4.1 92.6 91.3, 93.7 97.5 97.1, 97.8
January 1, 2006–December 31, 2006  60 4.3 3.8, 4.7 89.7 88.1, 91.1 97.2 96.8, 97.6
January 1, 2007–December 31, 2007  47 6.8 6.4, 7.3 68.3 66.1, 70.4 97.5 97.2, 97.8
Overall  56 5.1 4.8, 5.1 84.1 83.2, 85.0 97.5 97.3, 97.7
Abbreviation: CI, conﬁdence interval.
a The cutpoint for delinquency was December 31, 2007, for all cohorts.
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suggesting that the majority of missed visits had occurred
only a few months earlier. However, we consistently ob-
served a smaller peak for follow-up losses, generally coin-
ciding with the year of enrollment for each cohort. This
suggests a high rate of attrition early in a patient’s ART
course, with unreported early mortality being a likely and
important contributor to these losses (26).
Arbitrary and variable deﬁnitions of loss to follow-up in
ART programs are now extant, limiting the usefulness of
monitoring and evaluation activities within and across pro-
grams. Here we have proposed a simple approach to deter-
mining the best-performing criterion for classifying patients
as lost to follow-up. On the basis of data from the multisite
Lusaka program, we suggest a 2-month (60-day) lateness
threshold for deﬁning loss to follow-up. Since the basic data
needed to calculate such thresholds are found in many elec-
tronic medical records in sub-Saharan Africa (27), this
method should be considered for program-, country-, and/or
region-speciﬁc deﬁnitions of loss to follow-up.
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